Humanigen, Inc. is a biopharmaceutical company that focuses on preventing and treating cytokine storm, an immune hyper-response. Lenzilumab, an antibody that neutralizes GM-CSF, is being developed as a treatment for cytokine storm associated with COVID-19 and other inflammatory conditions. The company's pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab and HGEN005, which are being explored as treatments for glioblastoma multiforme and a range of eosinophilic diseases, respectively.